The Research Triangle is no stranger to the pharmaceutical industry, but newcomer Clintrax Global, Inc. is changing how the industry thinks about clinical trial contract negotiations.
The Research Triangle is no stranger to the pharmaceutical industry, but newcomer Clintrax Global, Inc. is changing how the industry thinks about clinical trial contract negotiations.
Clintrax Global opened for business in January 2013, with a mission to improve the way clinical trial contracts and budgets are negotiated. The company specializes as a functional service provider for pharmaceutical/biotechnology companies and contract research organizations (CROs) during the process of drug development. Clintrax provides these clients with worldwide contract and budget negotiation services with clinical trial sites including small clinics, large hospitals, and multicenter academic institutions.
Clintrax Global's unique business model is based on a seamless, centrally managed global footprint of in-country legal negotiators, which allows the company to execute agreements in over 60 countries in their local languages, and in accordance with each country's specific legal, regulatory and customary requirements. The company focuses on shortening negotiation times in order to minimize costly delays in the conduct of clinical trials. The sooner contracts are negotiated, the sooner the site can begin trial enrollment and provide knowledge about the drug.
Clintrax Global also offers a unique cloud-based tracking and reporting system, which allows clients to monitor and track the contract negotiation process in real time. This transparency gives clients the ability to ascertain the status of any individual contract throughout its life cycle.
Though the company is new, it brings together a team with years of experience, expertise, and success in clinical contracts. "Our personnel's breadth of local legal and budget negotiation experience in clinical trials allows us the flexibility to adapt to each client's needs on a global basis in order to quickly negotiate contracts while maintaining a high level of quality," says Clintrax Global Vice President of Operations, Elizabeth Easley. Clintrax Global endeavors to transform the contract negotiation service model in the clinical trial industry and looks forward to growth as the world's leading functional service provider for clinical trial contract negotiations.
Call Colin Dietch, (919) 322-2398 for more information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.